Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accumulated Expenses (2019 - 2025)

BridgeBio Pharma's Accumulated Expenses history spans 7 years, with the latest figure at $76.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 31.5% year-over-year to $76.7 million; the TTM value through Dec 2025 reached $76.7 million, up 31.5%, while the annual FY2025 figure was $76.7 million, 31.5% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $76.7 million at BridgeBio Pharma, up from $56.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $76.7 million in Q4 2025 and bottomed at $3.4 million in Q3 2024.
  • The 5-year median for Accumulated Expenses is $26.9 million (2022), against an average of $30.3 million.
  • The largest annual shift saw Accumulated Expenses plummeted 89.88% in 2024 before it skyrocketed 1544.84% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $37.0 million in 2021, then plummeted by 52.76% to $17.5 million in 2022, then rose by 1.49% to $17.8 million in 2023, then surged by 228.41% to $58.3 million in 2024, then soared by 31.5% to $76.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Accumulated Expenses are $76.7 million (Q4 2025), $56.2 million (Q3 2025), and $37.2 million (Q2 2025).